Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Biomed Pharmacother ; 163: 114860, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37196540

ABSTRACT

The antibiotic-induced intestinal injury (AIJ) is associated with diarrhoea and gastrointestinal discomfort. However, the pathological intestinal mechanisms and related side effects associated with antibiotic use/misuse may be counteracted by probiotics. This study aims to evaluate the effect and the protective mechanisms of a probiotic formulation containing Alkalihalobacillus clausii (formerly Bacillus clausii; BC) spores in an experimental model of AIJ. C57/Bl6J mice were orally challenged with a high dose of ceftriaxone for five days along with BC treatment which lasted up to the 15th day. Our results showed the beneficial effect of the probiotic in preserving colonic integrity and limiting tissue inflammation and immune cell infiltration in AIJ mice. BC increased tight junction expression and regulated the unbalanced production of colonic pro- and anti-inflammatory cytokines, converging toward the full resolution of the intestinal damage. These findings were supported by the histological evaluation of the intestinal mucosa, suggesting a potential restoration of mucus production. Notably, BC treatment increased gene transcription of the secretory products responsible for epithelium repair and mucus synthesis and normalized the expression of antimicrobial peptides involved in immune activation. Reconstruction of complex and diverse gut microbiota in antibiotic-induced dysbiosis was recorded upon BC supplementation. Specifically, the expansion of A. clausii, Prevotella rara and Eubacterium ruminatium drove intestinal microbiota rebalance by primarily impacting Bacteroidota members. Taken together, our data indicate that BC administration alleviates AIJ by multiple converging mechanisms leading to restoring gut integrity and homeostasis and reshaping microbiota composition.


Subject(s)
Bacillus clausii , Gastrointestinal Microbiome , Intestinal Diseases , Probiotics , Animals , Mice , Anti-Bacterial Agents/therapeutic use , Bacillus clausii/physiology , Spores, Bacterial , Intestinal Diseases/drug therapy , Intestinal Mucosa , Probiotics/pharmacology
2.
Biomed Pharmacother ; 153: 113528, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36076609

ABSTRACT

Paclitaxel (PTX) is one of the most broadly used chemotherapeutic agents for the treatment of several tumor types including ovarian, breast, and non-small cell lung cancer. However, its use is limited by debilitating side effects, involving both gastrointestinal and behavioral dysfunctions. Due to growing evidence showing a link between impaired gut function and chemotherapy-associated behavioral changes, the aim of this study was to identify a novel therapeutic approach to manage PTX-induced gut and brain comorbidities. Mice were pre-treated with sodium butyrate (BuNa) for 30 days before receiving PTX. After 14 days, mice underwent to behavioral analysis and biochemical investigations of gut barrier integrity and microbiota composition. Paired evaluations of gut functions revealed that the treatment with BuNa restored PTX-induced altered gut barrier integrity, microbiota composition and food intake suggesting a gut-to-brain communication. The treatment with BuNa also ameliorated depressive- and anxiety-like behaviors induced by PTX in mice, and these effects were associated with neuroprotective and anti-inflammatory outcomes. These results propose that diet supplementation with this safe postbiotic might be considered when managing PTX-induced central side effects during cancer therapy.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Gastrointestinal Microbiome , Intestinal Diseases , Lung Neoplasms , Animals , Butyric Acid/pharmacology , Carcinoma, Non-Small-Cell Lung/drug therapy , Dietary Supplements , Intestinal Diseases/drug therapy , Lung Neoplasms/drug therapy , Mice , Mice, Inbred C57BL , Paclitaxel/adverse effects
3.
Pharmacol Res ; 149: 104464, 2019 11.
Article in English | MEDLINE | ID: mdl-31553934

ABSTRACT

Patients with ulcerative colitis (UC) using marijuana have been reported to experience symptomatic benefit. Cannabidivarin (CBDV) is a safe non-psychoactive phytocannabinoid able to activate and desensitize TRPA1, a member of the TRP channels superfamily, which plays a pivotal role in intestinal inflammation. Here, we have investigated the potential intestinal anti-inflammatory effect of CBDV in mice and in biopsies from pediatric patients with active UC. Colonic inflammation was induced in mice by dinitrobenzenesulfonic acid (DNBS). The effect of orally administered CBDV on macroscopic and microscopic damage, inflammatory parameters (i.e. myeloperoxidase activity, intestinal permeability and cytokine production) and faecal microbiota composition, was evaluated 3 days after DNBS administration. TRPA1 expression was studied by RT-PCR in inflamed colons of mice as well as in mucosal colonic biopsies of children with active UC, whose response to incubation with CBDV was also investigated. CBDV attenuates, in a TRPA1-antagonist sensitive manner, DNBS-induced signs of inflammation including neutrophil infiltration, intestinal permeability, and cytokine (i.e. IL-1ß, IL-6 and the chemokine MCP-1) production. CBDV also alters the dysregulation of gut microbiota associated to colitis. Finally, CBDV lessens cytokine expression in colonic biopsies from pediatric patients with ulcerative colitis, a condition in which TRPA1 was up-regulated. Our preclinical study shows that CBDV exerts intestinal anti-inflammatory effects in mice via TRPA1, and in children with active UC. Since CBDV has a favorable safety profile in humans, it may be considered for possible clinical trials in patients with UC.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cannabinoids/therapeutic use , Colitis, Ulcerative/drug therapy , Cytokines/analysis , Inflammation/drug therapy , Animals , Child , Colitis, Ulcerative/genetics , Colitis, Ulcerative/pathology , Humans , Inflammation/genetics , Inflammation/pathology , Intestines/drug effects , Intestines/pathology , Male , Mice , TRPA1 Cation Channel/genetics , Up-Regulation/drug effects
4.
Int J Surg Case Rep ; 51: 277-281, 2018.
Article in English | MEDLINE | ID: mdl-30241087

ABSTRACT

INTRODUCTION: The authors present a "four-step" integrated surgical protocol to treat a rare case of multiple giant eccrine spiradenoma (ES) of the head and neck in a young patient. PRESENTATION OF CASE: An 18-year-old female patient presented with multiple swellings in the head and neck regions. The patient had a severe psychological trauma with a negative impact on her social life. Physical examination revealed multiple papulo-nodular swellings measuring between 5 cm × 8 cm and up to 10 cm × 20 cm in size with cerebriform aspect and soft consistency. Major lesions were located in the scalp, frontal area, neck, occipitotemporal, and retroauricular regions. Tissue biopsy found a benign composite adnexal neoplasm consisted in ES, trichoepithelioma, and cylindroma, a typical feature of Brooke-Spiegler Syndrome. A staged excision was planned, and available reconstructive options were considered. Scalp reconstruction included tissue expansions, advancement flaps, skin grafts, and dermal regeneration template (Integra®). All treatments were successful, and no recurrence was observed. The patient returned to a normal social life, and a radical excision with satisfying aesthetic results was achieved. DISCUSSION: Although adnexal tumors are benign in most of the cases, these lesions are prone to arise in the craniofacial region, thereby causing aesthetic discomfort associated with pain, hemorrhage, and infection to the patient every day. Furthermore, there is a potential risk of malignant transformation. These concerns demonstrate the need to establish a surgical protocol for the treatment of adnexal tumors. CONCLUSIONS: Our integrated surgical approach showed excellent aesthetic and functional results with benefits to the patient's life and complete oncological excision.

6.
Nucleic Acids Res ; 39(6): 1993-2006, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20952403

ABSTRACT

Although it is well known that RET gene is strongly activated by retinoic acid (RA) in neuroblastoma cells, the mechanisms underlying such activation are still poorly understood. Here we show that a complex series of molecular events, that include modifications of both chromatin and DNA methylation state, accompany RA-mediated RET activation. Our results indicate that the primary epigenetic determinants of RA-induced RET activation differ between enhancer and promoter regions. At promoter region, the main mark of RET activation was the increase of H3K4me3 levels while no significant changes of the methylation state of H3K27 and H3K9 were observed. At RET enhancer region a bipartite chromatin domain was detected in unstimulated cells and a prompt demethylation of H3K27me3 marked RET gene activation upon RA exposure. Moreover, ChIP experiments demonstrated that EZH2 and MeCP2 repressor complexes were associated to the heavily methylated enhancer region in the absence of RA while both complexes were displaced during RA stimulation. Finally, our data show that a demethylation of a specific CpG site at the enhancer region could favor the displacement of MeCP2 from the heavily methylated RET enhancer region providing a novel potential mechanism for transcriptional regulation of methylated RA-regulated loci.


Subject(s)
Chromatin/metabolism , DNA Methylation , Proto-Oncogene Proteins c-ret/genetics , Transcriptional Activation , Tretinoin/pharmacology , Cell Line, Tumor , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA-Binding Proteins/metabolism , Enhancer Elements, Genetic , Enhancer of Zeste Homolog 2 Protein , Epigenesis, Genetic , Histone Deacetylase 1/metabolism , Humans , Methyl-CpG-Binding Protein 2/metabolism , Neuroblastoma , Polycomb Repressive Complex 2 , Promoter Regions, Genetic , Receptors, Retinoic Acid/metabolism , Repressor Proteins/metabolism , Response Elements , Retinoic Acid Receptor alpha , Sin3 Histone Deacetylase and Corepressor Complex , Transcription Factors/metabolism
7.
Oral Microbiol Immunol ; 22(5): 313-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17803628

ABSTRACT

INTRODUCTION: Streptococcus mutans exhibits extensive genotypic diversity, but the role of this variation is poorly understood. This study aimed to determine the number and distribution of genotypes of S. mutans isolated from caries-active and caries-free children and to evaluate some of their phenotypic traits. METHODS: Stimulated saliva, tongue surface and biofilms over sound and carious teeth surfaces were sampled from 10 caries-free and 11 caries-active children aged 5-8 years. A total of 339 isolates of S. mutans were genotyped by arbitrarily primed polymerase chain reaction using OPA2 primer. One isolate from each genotype was tested for its acid susceptibility and its ability to form a biofilm. RESULTS: Fifty-one distinct genotypes were determined, one to three genotypes in each oral sample. A single genotype was detected in seven children, whereas the remaining 14 children exhibited two to seven genotypes. There were no significant differences in the number of genotypes detected in caries-free and caries-active children. No correlation was observed between the number of genotypes and the mutans streptococci salivary levels. Five of the six high biofilm-forming genotypes were obtained from caries-active children, although the differences in biofilm formation between isolates from caries-free and caries-active children were not statistically significant. Genotypes with low susceptibility to acid challenge were statistically more frequent among isolates from caries-active children than among those from caries-free children. CONCLUSION: The present data suggested that there were differences in the distribution of genotypes of S. mutans according to the oral site and that S. mutans populations differ in their acid susceptibility and ability to form biofilms, factors allowing their colonization of sucrose-rich environments.


Subject(s)
Dental Caries/microbiology , Mouth/microbiology , Streptococcus mutans/genetics , Acids , Biofilms , Child , Child, Preschool , Colony Count, Microbial , DMF Index , DNA Primers , Genetic Variation/genetics , Genotype , Humans , Phenotype , Polymerase Chain Reaction , Saliva/microbiology , Streptococcus mutans/classification , Streptococcus mutans/isolation & purification , Tongue/microbiology , Tooth/microbiology
8.
Am J Pathol ; 159(4): 1225-30, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11583949

ABSTRACT

The RING-finger protein RNF4 modulates both steroid-receptor-dependent and basal transcription and interacts with a variety of nuclear proteins involved in cell growth control. RNF4 is expressed at very high levels in testis and at much lower levels in several other tissues. We show that in germ cells RNF4 expression is strongly modulated during progression of spermatogonia to spermatids, with a peak in spermatocytes. Analysis of human testicular germ cell tumors shows that RNF4 is not expressed in all tumors analyzed including seminomas, the highly malignant embryonal carcinomas, yolk sac, and mixed germ cell tumors. We also show that the ectopically expressed RNF4 gene inhibits cell proliferation of both somatic and germ cell tumor-derived cells. Mutation of critical cysteine residues in the RING finger domain abolished the RNF4 growth inhibition activity. Our results suggest that the lack of RNF4 expression may play a role in the progression of testicular tumors.


Subject(s)
DNA-Binding Proteins/metabolism , Growth Inhibitors/metabolism , Nuclear Proteins , Spermatozoa/metabolism , Testicular Neoplasms/metabolism , Transcription Factors , Animals , Cell Division/drug effects , Cellular Senescence/physiology , DNA-Binding Proteins/pharmacology , Growth Inhibitors/pharmacology , Humans , Immunohistochemistry , Male , Mice , Mice, Inbred Strains , Reference Values , Spermatozoa/cytology , Spermatozoa/physiology , Testis/metabolism , Tumor Cells, Cultured , Ubiquitin-Protein Ligases
9.
FEBS Lett ; 500(1-2): 41-4, 2001 Jun 29.
Article in English | MEDLINE | ID: mdl-11434923

ABSTRACT

The tyrosine phosphatase r-PTPeta is able to suppress the malignant phenotype of rat thyroid tumorigenic cell lines. To identify r-PTPeta interacting proteins, a yeast two-hybrid screening was performed and an insert corresponding to the full-length syntenin cDNA was isolated. It encodes a protein containing two PDZ domains that mediates the binding of syntenin to proteins such as syndecan, proTGF-alpha, beta-ephrins and neurofascin. We show that r-PTPeta is able to interact with syntenin also in mammalian cells, and although syntenin is a tyrosine-phosphorylated protein it is not a substrate of r-PTPeta. The integrity of both PDZ domains of syntenin and the carboxy-terminal region of r-PTPeta are required for the interaction between syntenin and r-PTPeta.


Subject(s)
Carrier Proteins/metabolism , Intracellular Signaling Peptides and Proteins , Membrane Proteins , Protein Tyrosine Phosphatases/metabolism , Carrier Proteins/chemistry , Cells, Cultured , Humans , Precipitin Tests , Protein Structure, Tertiary , Receptor-Like Protein Tyrosine Phosphatases, Class 3 , Syntenins , Two-Hybrid System Techniques
10.
Int J Oncol ; 17(5): 1015-8, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11029506

ABSTRACT

Galectin-1 has been demonstrated to be a mediator of T-cell apoptosis acting on activated T-cells and, in a selective manner, on different T leukemia cell lines. Here we show that the sensitivity to galectin-1 is associated with repression of the endogenous galectin-1 gene whereas non-sensitive cells express high levels of galectin-1. Repression of galectin-1 gene in sensitive cells is associated with hyper-methylation of the promoter region. Transient treatment of non-expressing cells with the demethylating agent 5-azacytidine led to irreversible demethylation and subsequent reactivation of galectin-1 gene.


Subject(s)
DNA Methylation , Gene Expression Regulation, Leukemic , Hemagglutinins/genetics , Leukemia, T-Cell/pathology , Neoplasm Proteins/genetics , Antimetabolites, Antineoplastic/pharmacology , Azacitidine/pharmacology , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/drug effects , Enzyme Inhibitors/pharmacology , Galectin 1 , Gene Expression Regulation, Leukemic/drug effects , Hemagglutinins/biosynthesis , Humans , Leukemia, T-Cell/genetics , Leukemia, T-Cell/metabolism , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/biosynthesis , Promoter Regions, Genetic , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism
11.
J Biol Chem ; 275(11): 7894-901, 2000 Mar 17.
Article in English | MEDLINE | ID: mdl-10713105

ABSTRACT

We have identified a novel human gene encoding a 59-kDa POZ-AT hook-zinc finger protein (PATZ) that interacts with RNF4, a mediator of androgen receptor activity, and acts as a transcriptional repressor. PATZ cDNA was isolated through a two-hybrid interaction screening using the RING finger protein RNF4 as a bait. In vitro and in vivo interaction between RNF4 and PATZ was demonstrated by protein-protein affinity chromatography and coimmunoprecipitation experiments. Such interaction occurred through a small region of PATZ containing an AT-hook DNA binding domain. Immunofluorescence staining and confocal microscopy showed that PATZ localizes in distinct punctate nuclear regions and colocalizes with RNF4. Functional analysis was performed by cotransfection assays: PATZ acted as a transcriptional repressor, whereas its partner RNF4 behaved as a transcriptional activator. When both proteins were overexpressed a strong repression of the basal transcription was observed, indicating that the association of PATZ with RNF4 switches activation to repression. In addition, RNF4 was also found to associate with HMGI(Y), a chromatin-modeling factor containing AT-hook domains.


Subject(s)
Neoplasm Proteins , Nuclear Proteins , Repressor Proteins/metabolism , Zinc Fingers , Amino Acid Sequence , Animals , DNA-Binding Proteins/metabolism , HMGA1a Protein , High Mobility Group Proteins/metabolism , Humans , Kruppel-Like Transcription Factors , Mice , Molecular Sequence Data , Protein Binding , Repressor Proteins/classification , Repressor Proteins/genetics , Sequence Homology, Amino Acid , Transcription Factors/metabolism , Transcription, Genetic , Two-Hybrid System Techniques , Ubiquitin-Protein Ligases
SELECTION OF CITATIONS
SEARCH DETAIL
...